gut‐liver axis

  • 文章类型: Journal Article
    食物来源的细胞外囊泡(FEV)是从母乳等膳食材料中获得的纳米级膜囊泡,植物和益生菌。与其他电动汽车不同,FEV可以在胃肠道中的恶劣降解条件下存活并到达肠道。这种独特的功能使FEV成为健康和口腔纳米医学中用于肠道疾病的有前途的益生元,如炎症性肠病。有趣的是,最近在非胃肠道疾病中也观察到了FEV的治疗效果。然而,机制仍不清楚甚至神秘。据推测,口服FEV可以进入血液,到达偏远的器官,从而在其中发挥治疗作用。然而,新出现的证据表明,到达胃肠道以外器官的FEV的量是微不足道的,并且可能不足以解释涉及肝脏等远程器官的疾病所取得的显着治疗效果。因此,我们在此提出,FEV主要通过调节肠道微环境,如屏障完整性和微生物群,在肠道中局部发挥作用。从而通过肠-肝轴在非胃肠道疾病中远程引发对肝脏的治疗影响。同样,通过FEV递送至胃肠系统的药物可能通过肠-肝轴起作用。由于肝脏是主要的代谢枢纽,肠道微环境可能与其他代谢疾病有关。事实上,许多非酒精性脂肪性肝病患者,肥胖,糖尿病和心血管疾病患有漏肠和生态失调。在这次审查中,我们概述了FEV的最新进展,并讨论了它们作为治疗剂和药物递送系统的生物医学应用,强调肠-肝轴在FEV治疗肠道疾病和代谢性疾病的作用机制中的关键作用。
    Food-derived extracellular vesicles (FEVs) are nanoscale membrane vesicles obtained from dietary materials such as breast milk, plants and probiotics. Distinct from other EVs, FEVs can survive the harsh degrading conditions in the gastrointestinal tract and reach the intestines. This unique feature allows FEVs to be promising prebiotics in health and oral nanomedicine for gut disorders, such as inflammatory bowel disease. Interestingly, therapeutic effects of FEVs have recently also been observed in non-gastrointestinal diseases. However, the mechanisms remain unclear or even mysterious. It is speculated that orally administered FEVs could enter the bloodstream, reach remote organs, and thus exert therapeutic effects therein. However, emerging evidence suggests that the amount of FEVs reaching organs beyond the gastrointestinal tract is marginal and may be insufficient to account for the significant therapeutic effects achieved regarding diseases involving remote organs such as the liver. Thus, we herein propose that FEVs primarily act locally in the intestine by modulating intestinal microenvironments such as barrier integrity and microbiota, thereby eliciting therapeutic impact remotely on the liver in non-gastrointestinal diseases via the gut-liver axis. Likewise, drugs delivered to the gastrointestinal system through FEVs may act via the gut-liver axis. As the liver is the main metabolic hub, the intestinal microenvironment may be implicated in other metabolic diseases. In fact, many patients with non-alcoholic fatty liver disease, obesity, diabetes and cardiovascular disease suffer from a leaky gut and dysbiosis. In this review, we provide an overview of the recent progress in FEVs and discuss their biomedical applications as therapeutic agents and drug delivery systems, highlighting the pivotal role of the gut-liver axis in the mechanisms of action of FEVs for the treatment of gut disorders and metabolic diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    天然来源的多糖可以通过“肠-肝轴”途径调节肠道菌群的组成,可能改善酒精性肝损伤。Aspalathuslinearis,也被称为路易波斯,是一种在这方面显示出希望的天然产品。这项研究观察了A.linearis多糖(ALP)的结构特性以及它对治疗急性酒精性肝损害的作用。这项研究着眼于单糖的组成,功能组,和新发现的水溶性多糖的分子量(Mw),名为ALP。多糖由吡喃糖环组成,酰胺基团,和硫酸基团通过β-糖苷键连接。它的相对Mw为4.30×103kDa,由葡萄糖组成,鼠李糖,和其他一些单糖。研究发现,ALP治疗小鼠急性酒精性肝病模型可减轻病理症状,抑制炎症细胞因子的释放,并抑制氧化应激指标。实验表明,不同剂量的ALP可以激活P4502E1/Keap1-Nrf2-HO-1信号通路。炎症因子和下游抗氧化酶的调节由此发生。基于这些数据,ALP可能通过减少氧化应激相关损伤,通过“肠-肝轴”途径保护肝脏,炎症,和酒精相关的肠道微生物组的改变。结果表明,ALP减轻了氧化应激引起的损伤,炎症反应,以及酒精通过“肠-肝轴”途径诱导的肠道微生物群的变化,为肝脏提供保护。这为相关药物的开发提供了初步证据。实际应用:研究人员从黑木耳的新鲜叶中提取了一种多糖。将多糖纯化并测定为具有主要均一的分子量。建立急性酒精性肝损伤小鼠模型,结论是多糖可以通过“肠-肝轴”途径改善小鼠的肝损伤。这种新型多糖可用作添加剂,开发具有有益效果的功能性食品,这可以积极影响消费者的日常维护。
    Polysaccharides from natural sources can regulate the composition of intestinal flora through the \"gut-liver axis\" pathway, potentially ameliorating alcoholic liver injury. Aspalathus linearis, also known as rooibos, is one such natural product that has shown promise in this regard. This study looked at the structural properties of A. linearis polysaccharide (ALP) and how well it would work to treat acute alcoholic liver impairment. This study looks at the composition of monosaccharides, functional groups, and molecular weight (Mw) of a newly discovered water-soluble polysaccharide, named ALP. The polysaccharide is composed of pyranose rings, amide groups, and sulfate groups linked by β-glycosidic linkage. It has a relative Mw of 4.30 × 103 kDa and is composed of glucose, rhamnose, and some other monosaccharides. The study found that treating mice with the model of acute alcoholic liver disease with ALP could alleviate pathological symptoms, inhibit the release of inflammatory cytokines, and suppress indicators of oxidative stress. Experiments have shown that different doses of ALP can activate the P4502E1/Keap1-Nrf2-HO-1 signaling pathway. The regulation of inflammatory factors and downstream antioxidant enzymes occurs as a result. Based on these data, it is likely that ALP protects the liver via the \"gut-liver axis\" pathway by reducing oxidative stress-related damage, inflammation, and alcohol-related alterations to the gut microbiome. The results indicate that ALP mitigates injury caused by oxidative stress, inflammatory responses, and changes in the gut microbiota induced by alcohol through the \"gut-liver axis\" pathway, which provides protection to the liver. This provides preliminary evidence for the development of related drugs. PRACTICAL APPLICATION: Researchers extracted a polysaccharide from fresh leaves of Auricularia auricula. The polysaccharide was purified and determined to have a predominantly homogeneous molecular weight. An acute alcoholic liver damage mouse model was established, and it was concluded that the polysaccharide could ameliorate liver injury in mice through the \"gut-liver axis\" pathway. This novel polysaccharide can be used as an additive to develop functional foods with beneficial effects, which can positively impact the daily maintenance of consumers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号